Loblaw 3Q Profit, Sales Rise
By Adriano Marchese
Loblaw's profit rose in the third quarter thanks to a dual boost from increased shopper visits and larger purchases that helped drive sales.
The Canadian food-and-pharmacy retail giant on Wednesday posted net income of 794 million Canadian dollars ($566.3 million), or C$0.66 a share, up from C$777 million, or C$0.63 a share, in the comparable quarter a year earlier.
Adjusted earnings were C$0.69 a share. According to FactSet, analysts were expecting C$0.68 a share.
Revenue rose to C$19.4 billion from C$18.54 billion a year earlier, just edging over analyst forecasts of a rise to C$19.39 billion.
Food-retail same-store sales growth was 2% in the quarter, while drug retail saw 4% growth. For pharmacy and healthcare services, same-store sales were up 5.9%, and for front store they climbed 1.9%.
The cost of food has been top of mind for many Canadians over the past years, but Loblaw said customers have both been coming in more frequently and buying more per visit. The company also said its internal food inflation was lower than the 3.6% consumer price index for food purchased from stores.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 12, 2025 07:17 ET (12:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
